Immune-related adverse events (irAE) can develop in patients treated with immune checkpoint inhibitors (ICIs). For example, ICI treatment can increase the risk of myocarditis as a lethal irAE,1 with a mortality rate up to 50%.2 However, the frequency of ICI-related myocarditis is low, and thus the detailed pathogenic mechanisms and risk factors remain unknown. General myocarditis and ICI-related myocarditis have distinct manifestations, suggesting different risk factors; however, the differences of risk factors in these 2 types are unclear.
Zamami Y, Niimura T, Okada N, et al. Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis. JAMA Oncol. 2019;5(11):1635–1637. doi:10.1001/jamaoncol.2019.3113
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: